Should You Buy InspireMD Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, InspireMD Inc. (NSPR) carries a solid Quality of Company rating of 6.2/10. Trading at $0.70, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 4 of 7 CirclFi valuation models project upside for InspireMD Inc. (NSPR) at $0.69 — the model consensus leans bullish, with a Quality Score of 6.2/10 and Value-Trap risk of 36/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
Investment Thesis
The Bull Case
Target: $1.75 (+151.6% upside)
- According to the CirclFi Deep Alpha Valuation Engine, the gap between the market price of $0.70 and the composite fair value of $0.79 implies +13.5% upside potential.
- According to the CirclFi Deep Alpha Valuation Engine, the EROIC Spread model targets a fair value of $1.75 (+151.6%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
The Bear Case
Target: $0.11 (-83.7%)
- According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $0.11 (-83.7%), suggesting that the market price embeds overly optimistic growth assumptions.
- According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +235.3% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.
The Bottom Line
Our models don't have a clear verdict on InspireMD Inc.. At $0.70 vs. $0.79 composite fair value, the average upside of +13.5% masks significant model disagreement (+235.3% spread). With quality at 6.2/10, this is a stock where the margin of error is wide and additional fundamental research is strongly recommended.
These are quantitative model outputs, not investment recommendations. InspireMD Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
Frequently Asked Questions
Should I buy NSPR stock right now?
Based on CirclFi's multi-model analysis, 4 of 7 models see upside for NSPR at $0.69. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 6.2/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in InspireMD Inc.?
Key risks include: limited model coverage (7/13 active), reducing analytical confidence; wide model disagreement (1447% spread), signaling high uncertainty; general market and sector-specific risks affecting Surgical & Medical Instruments & Apparatus companies. Always diversify and consult a financial advisor.
How does NSPR compare to its competitors?
Among Surgical & Medical Instruments & Apparatus peers, NSPR holds a Quality Score of 6.2/10. Comparable companies include DXCM (QOC 10.0), IRMD (QOC 10.0), PODD (QOC 10.0). The relative ranking helps investors identify whether NSPR offers better fundamental quality than alternatives in the same sector.
Is NSPR a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. NSPR's Quality Score of 6.2/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy NSPR at?
CirclFi does not provide target buy prices or price alerts. However, our 7 active models produce fair value estimates ranging from $0.11 to $1.75. At $0.69, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for NSPR.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad